2021
DOI: 10.1200/jco.2021.39.15_suppl.e18011
|View full text |Cite
|
Sign up to set email alerts
|

Circulating tumor cells demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh.

Abstract: e18011 Background: Tobacco consumption accounts for 1.6 million deaths annually in the South East Asia Region (SEAR). Notably, amongst 10-20% of the global population consuming the betel quid and tobacco, about 81% concentration is in SEAR regions, including India and Bangladesh. The prevalence of HNSCC in these regions is rising alarmingly. For example, HNCs account for 23% of total 156775 cancer incidences in Bangladesh. Liquid biopsy tools are unavailable and expensive for most patients in this region. How… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Initial efforts for liquid biopsies in head and neck cancer have shown encouraging results, particularly with nasopharyngeal carcinoma and human papilloma virus-positive HNSCCs [ 10 , 11 ]. Studies have tried to establish CTCs as a positive biomarker in HNSCC [ 12 ]. Recently, Qayyumi et al [ 13 ] demonstrated the utility of preoperative CTCs to investigate aggressive clinicopathologic factors in the treatment-naïve oral squamous cell carcinoma patients.…”
Section: Introductionmentioning
confidence: 99%
“…Initial efforts for liquid biopsies in head and neck cancer have shown encouraging results, particularly with nasopharyngeal carcinoma and human papilloma virus-positive HNSCCs [ 10 , 11 ]. Studies have tried to establish CTCs as a positive biomarker in HNSCC [ 12 ]. Recently, Qayyumi et al [ 13 ] demonstrated the utility of preoperative CTCs to investigate aggressive clinicopathologic factors in the treatment-naïve oral squamous cell carcinoma patients.…”
Section: Introductionmentioning
confidence: 99%
“…Current clinically relevant CTC isolation methods validated by regulatory authorities (e.g. FDA-approved CellSearch®, 15 DCG(I)-approved OncoDiscover®, 6,[16][17][18][19] etc.) include a CTC enrichment step followed by a subsequent detection stage.…”
Section: Introductionmentioning
confidence: 99%